SCHEMBL10141834 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	MAPK1	P28482	8/20	0.50

▸	MAP4K1	Q92918	1/20	0.40

▸	ATM	Q13315	8/20	0.40

▸	ATR	Q13535	8/20	0.40

▸	GSK3B	P49841	3/20	0.40

▸	PRKDC	P78527	4/20	0.39

▸	SYK	P43405	3/20	0.39

▸	JAK2	O60674	1/20	0.39

▸	ABL1	P00519	1/20	0.39

▸	KIT	P10721	1/20	0.39

▸	SERPINA2	P20848	1/20	0.39

▸	PIK3R1	P27986	1/20	0.39

▸	FLT4	P35916	1/20	0.39

▸	FLT3	P36888	1/20	0.39

▸	PIK3CA	P42336	1/20	0.39

▸	MTOR	P42345	1/20	0.39

▸	GSK3A	P49840	1/20	0.39

▸	MAP3K9	P80192	1/20	0.39

▸	KCNH2	Q12809	1/20	0.39

▸	MERTK	Q12866	1/20	0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL665595	0.85	MAPK1 (0.69)	MAPK1MAP4K1ATMATRPRKDC
SCHEMBL10141819	0.85	MAPK1 (0.57)	MAPK1MAP4K1ATMATRGSK3B
SCHEMBL9985339	0.82	MAPK1 (0.50)	MAPK1MAP4K1ATMATRGSK3B
SCHEMBL666905	0.81	MAPK1 (0.51)	MAPK1MAP4K1SYK
SCHEMBL9985558	0.81	MAPK1 (0.46)	MAPK1MAP4K1ATMATRGSK3B
SCHEMBL10141820	0.81	MAPK1 (0.53)	MAPK1MAP4K1ATMATRGSK3B
SCHEMBL666892	0.79	MAPK1 (0.51)	MAPK1ATMATRGSK3BPRKDC
SCHEMBL10141891	0.79	MAPK1 (0.45)	MAPK1MAP4K1ATMATRGSK3B
SCHEMBL667527	0.79	MAPK1 (0.47)	MAPK1MAP4K1ATMATRGSK3B
SCHEMBL10141812	0.79	MAPK1 (0.49)	MAPK1MAP4K1ATMATRPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20160009723-A1	COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE	VERTEX PHARMACEUTICALS INCORPORATED (US)	2016-01-14	—	—	US	disclosed
US-20160009723-A1	COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE	VERTEX PHARMACEUTICALS INCORPORATED (US)	2016-01-14	—	—	US	disclosed
US-20140288347-A1	COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-09-25	—	—	US	disclosed
US-20140288347-A1	COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-09-25	—	—	US	disclosed
US-8623869-B2	Compounds useful as inhibitors of ATR kinase	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-01-07	—	—	US	disclosed
US-8623869-B2	Compounds useful as inhibitors of ATR kinase	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-01-07	—	—	US	disclosed
US-20120046295-A1	COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE	VERTEX PHARMACEUTICALS INCORPORATED (US)	2012-02-23	—	—	US	disclosed
US-20120046295-A1	COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE	VERTEX PHARMACEUTICALS INCORPORATED (US)	2012-02-23	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20140288347-A1	COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE	ATR, CHEK1, MAP3K5	MAPK1 122/4885MAP4K1 27/4885ATM 50/4885
US-20120046295-A1	COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE	ATR, CHEK1, MAP3K5	MAPK1 122/4885MAP4K1 27/4885ATM 50/4885
US-20160009723-A1	COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE	ATR, CHEK1, MAP3K5	MAPK1 122/4885MAP4K1 27/4885ATM 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.